Title: Managed Care Review Board - Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders Web Activity
Topic: Endocrinology
Relevant Terms: Growth Hormone Deficiency, Growth Hormone Disorders, Growth Hormone Replacement Therapy, Managed Care, Recombinant Human Growth Hormone
Primary Audience: Managed Care: Medical Directors, Pharmacists, Pharmacy Directors; Physicians; Registered Nurses
Launch Date: 30-May-13
Credits: 1.5 AMA PRA Category 1 Credits
1.5 ACPE contact hours
1.5 ANCC contact hours
Expiration Date: 30-Nov-14
Curriculum Name: The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders Web Activity

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Assess the clinical and psychosocial implications caused by the effects of GHD and growth-related disorders
  2. Implement clinical practice guidelines for GHD and growth-related disorders that ensure early and accurate diagnoses, testing requirements, coding, treatment considerations, and follow-up for optimal patient outcomes
  3. Employ pharmacoeconomic modeling and other decision support tools to appropriately invest resources on GH replacement therapy
  4. Provide accurate and appropriate counsel as part of the care team
  5. Provide appropriate care and counsel for patients and their families

    Faculty

    Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
    Medical Director
    HumanaOne
    Milwaukee, Wisconsin


    Linda Bevington, RN, BSN, CPN
    Patient/Family Educator
    Family Learning Center
    Children's Hospital of Philadelphia
    Philadelphia, PA


    Pinchas Cohen, MD
    Professor and Chief of Endocrinology
    Mattel Children's Hospital
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA


    Terri H. Lipman, PhD, CRNP, FAAN
    Miriam Stirl Endowed Term Professor of Nutrition
    Professor of Nursing of Children
    University of Pennsylvania School of Nursing
    Philadelphia, PA


    Mark E. Molitch, MD
    Professor of Medicine
    Endocrinology
    Northwestern University Feinberg School of Medicine
    Chicago, IL


    Nancy A. Nickman, PhD, RPh
    Professor of Pharmacotherapy
    Department of Pharmacotherapy
    University of Utah College of Pharmacy
    Salt Lake City, UT


    Jointly sponsored/coprovided by the Postgraduate Institute for Medicine and Impact Education, LLC
    www.impactedu.net             www.pimed.com
             

    The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders


     
    Supported by an educational grant from Novo Nordisk, Inc.

    Estimated time to complete activity
    : 1.5 hours

    Target Audience

    • Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
    • Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for growth/growth disorders including: physicians, pharmacists, registered nurses, and case managers

    Special Offering
    Video demonstration of various recombinant human growth hormone (rhGH) administration devices by a nurse specialist.

    Statement of Need

    The treatment of children with recombinant human growth hormone (rhGH) can be effective for increasing height toward normalization in all indications, particularly in children with growth hormone deficiency (GHD). Some studies have shown that children with idiopathic short stature (ISS) and GHD suffer from stress and other emotional and behavioral problems. Adults with GHD receiving rhGH therapy show improvements in body composition, quality of life, and surrogate markers for cardiovascular disease.  

    The treatment of GHD and growth-related disorders present distinct challenges for MCOs, payers, and affiliated providers. Balancing resource allocation with patient safety and optimal clinical outcome is paramount to payers and patients alike. Informed decisions are needed about the optimal role of GH replacement therapy so that patients who will benefit most are sure to receive it. This activity will address the educational needs of the target audience to enhance the health and well-being of many health plan patients, both children and adults, who suffer from GHD and growth-related disorders.

    Physician Accreditation Statement

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacist Accreditation Statement
    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

     
    Credit Designation
    Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (1.5 CEUs) of the Accreditation Council for Pharmacy Education.
    (Universal Activity Number – 0809-9999-13-200-H01-P)

    Type of Activity: Application

    For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

    Nursing Continuing Education

    Credit Designation
    This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

    Accreditation Statements
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Name of Faculty or Presenter
    Reported Financial Relationship
    Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
    Consulting Fees: Amylin Pharmaceuticals Inc.
    Linda Bevington, RN, BSN, CPN No financial interest/relationships relating to the topic of this activity
    Pinchas Cohen, MD Consulting Fees: Novo Nordisk, Inc.
    Terri H. Lipman, PhD, CRNP, FAAN Consulting Fees: Roche, Inc.
    Mark E. Molitch, MD
    Consulting Fees: Novo Nordisk, Inc.
    Contracted Research: Novo Nordisk, Inc. and Eli Lilly and Company
    Nancy A. Nickman, PhD, RPh
    Contracted Research: Amgen Inc. and Novartis Pharmaceuticals Corporation
     
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 
     
    Planner:
    Steven Casebeer, MBA

    Has nothing to disclose.
     
    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period May 30, 2013 through November 30, 2014, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the embedded questions within the activity; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

    For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

    Media
    Internet

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Hardware/Software Requirements
    Google Chrome for Windows, Mac, or Linux
    Internet Explorer 7.0+ for Windows
    Mozilla 1.4+ for Windows, Mac, or Linux
    Firefox 3.5+ for Windows, Mac, or Linux
    Safari 4.0+ for Mac

    Fee Information
    There is no fee for this educational activity.
     
    Questions
    If you have any questions, please call (215) 619-8812 or email MCRB@impactedu.net